Every self-funded employer is feeling the same pressure right now. GLP-1 claims are landing on renewals in numbers nobody budgeted for, specialty drug costs keep climbing faster than wages, and a single high-cost claimant can undo a year of otherwise disciplined plan management. The instinct in that environment is to look for one big fix. There isn’t one. Healthcare cost containment for self-funded employers works because several smaller levers pull in the same direction at once, not because any single program solves the problem on its own.
This is a practical look at where the real savings come from: provider network strategy, high-cost claims and specialty drug management, reference-based pricing and plan design. None of these levers is a silver bullet, and a partner who tells you otherwise is usually selling something rather than solving something.
A small share of claims drives most of the spend
Before choosing tactics, effective healthcare cost containment starts with knowing where the money goes. On most self-funded plans, a small percentage of members generate the majority of claims cost, and that concentration has only gotten sharper as specialty drugs and complex chronic conditions take up a larger share of total spend. Medical cost containment strategies that ignore this concentration, and instead spread effort evenly across the whole population, tend to produce modest results at best.
The practical implication is that employers get more out of identifying and managing the claims that are already trending toward high cost than out of broad, population-wide initiatives alone. That doesn’t mean population health work has no value. It means it should sit alongside targeted claims management, not replace it.
Provider networks: Where you route care matters as much as what you pay for it
Network design is often treated as a one-time decision made at plan setup, but it’s one of the more durable cost containment levers available. Steering members toward higher-value providers, whether through a curated network, a direct-to-employer contract with a health system or tiered benefit design, changes unit cost without changing the benefit members experience.
This is also where administration and network strategy have to work together. A TPA that understands claims adjudication and eligibility as well as it understands network contracting can route claims correctly the first time, which prevents the kind of leakage that quietly erodes network savings before they ever show up in a renewal.
Direct contracting as a sharper version of network strategy
For employers with enough scale or geographic concentration, direct contracting with a health system takes network steerage a step further. It removes a layer of markup, gives employers more visibility into what they’re paying for, and often comes with better data access than a standard carrier network arrangement provides.
High-cost claims and specialty drugs: Managing the GLP-1 problem without just restricting access
GLP-1 medications are the clearest example of why cost containment has to be proactive rather than reactive. These drugs deliver real clinical value for diabetes and, increasingly, obesity management, which makes an outright coverage denial a poor long-term strategy for most employers. The more durable approach combines utilization management, prior authorization criteria tied to clinical guidelines and case management for members on these therapies, rather than a blanket exclusion that a workforce will push back on.
The same logic applies to high-cost claims generally. Early identification of members trending toward complex or catastrophic claims, paired with clinical case management and utilization review, gives employers a chance to influence a claim’s trajectory instead of just absorbing whatever it becomes. Waiting until a claim is already six figures removes almost every option except paying it.
Stop-loss coordination matters here too. A plan’s cost containment strategy and its stop-loss structure need to reflect the same view of risk, or the employer ends up exposed on exactly the claims the rest of the strategy was built to manage. Reviewing where administrative risk creates gaps in high-cost claim management is worth doing alongside any specialty drug strategy, not after it.
Reference-based pricing: A strong lever for the right plan, not a default for every plan
Reference-based pricing sets reimbursement against a defined benchmark, typically a percentage of Medicare rates, instead of a negotiated network discount. Done well, it can produce meaningful savings over a standard network arrangement. It also asks more of the employer and the plan administrator: member education, balance-billing protection and provider relations all need to be handled deliberately, or the savings on paper turn into member complaints in practice.
Reference-based pricing tends to work best for employers with the appetite to manage that member experience actively, and less well as a default choice for every plan population. A closer look at how reference-based pricing fits into plan design is worth having before assuming it’s the right lever for your group.
Plan design is what holds the other levers together
Network strategy, specialty drug management and pricing methodology all depend on plan design to function well together. Cost-sharing tiers that reward members for choosing lower-cost, higher-value care. Formulary and prior authorization rules that reflect clinical evidence instead of last year’s template. Real-time claims and eligibility data that lets an employer see a cost trend developing instead of finding out at renewal. Without that coordination, even strong claims analytics and reporting become a dashboard nobody acts on rather than a tool that changes plan performance.
Frequently asked questions
How do employers know which cost containment lever to prioritize first?
Start with claims data, not with whichever solution a vendor is currently pitching. If a small group of high-cost claimants or a specific drug category is driving disproportionate spend, claims and specialty drug management usually deliver value faster than a network overhaul. If unit cost across the board is the issue, network or pricing strategy tends to matter more.
Can reference-based pricing and a negotiated network coexist in the same plan?
Yes, and many employers run a hybrid rather than choosing one exclusively. A common structure applies reference-based pricing to certain service categories or out-of-network claims while keeping a negotiated network in place for core services, which limits member disruption while still capturing pricing savings where they matter most.
How should employers verify that a TPA’s reported savings are real and not just cost shifting?
Ask for the methodology behind the savings figure, not just the total. Savings that come from shifting cost to members through higher deductibles or narrower coverage will show up as lower paid claims without lowering total cost of care. Legitimate cost containment should be traceable to unit cost reduction, utilization change or claims accuracy, and a credible partner can show that breakdown.
Does investing in cost containment programs affect stop-loss underwriting or renewal pricing?
It can, though the effect shows up over time rather than immediately. Stop-loss carriers underwrite based on claims history and risk trend, so a plan that can document active case management, utilization review and specialty drug oversight is telling a different risk story than one relying on network discounts alone. That documentation doesn’t guarantee better renewal terms, but it gives brokers something concrete to present when negotiating them.
How often should a self-funded employer reassess its cost containment strategy?
At minimum, annually as part of renewal planning, but a mid-year check-in is worth adding if GLP-1 or other specialty drug utilization is trending upward. Cost drivers shift faster than plan documents typically get revisited, and a strategy built two renewal cycles ago may no longer match where the plan’s actual risk sits today.
Healthcare cost containment means building the right mix, not buying one solution
The employers who get the most out of healthcare cost containment aren’t the ones who found one program that fixed everything. They’re the ones who assembled the right combination of network strategy, claims management, pricing methodology and plan design for their specific population, and who have a partner willing to say when a popular solution isn’t the right fit for their plan.
BHPS works from that position deliberately. We aren’t a pharmacy benefit manager (PBM) and we don’t own a single network we’re incentivized to push regardless of fit. As a neutral third-party administrator, our role is to help self-funded employers assemble the mix of levers that fits their claims data, their workforce and their risk tolerance, and to administer that mix well once it’s built.
If rising specialty drug and high-cost claims trends are already showing up in your renewal, it’s worth reviewing your plan’s cost containment mix before the next plan year locks it in. Talk with the BHPS team about where your plan has room to move.